|
|
7/17/2006 11:13:25 AM ET
SWISS MEDICA TO PURSUE MILITARY AND INTERNATIONAL CONTRACTS WITH THE APPOINTMENT OF
CHRISTENSEN CO. AS STRATEGIC BUSINESS ADVISORS
FOR IMMEDIATE RELEASE
Stock Symbol: OTC BB: SWME
June 17, 2006
Toronto, Canada – Swiss Medica, Inc. (OTC BB: SWME) announced today its intention to pursue military and
international contracts with the appointment of Mr. Chad Christensen, Managing Director of Christensen Co., as
Strategic Business Advisor.
With a distinguished career in international banking, and advisor to several Fortune 500 companies, Mr.
Christensen brings to Swiss Medica a wealth of national and international contacts at all levels of business and
government. He will assist the Company in its continuing development of national and international markets.
Mr. Christensen is currently serving his second term in the Nevada State Legislature. He is also a Member of the
Globalization Board, George Washington University's Elliott School of International Affairs; a Member of the
Transportation & Homeland Security Committees, National Conference of State Legislatures (NCSL); a Member
of the Commerce and Economic Development Committee, American Legislative Exchange Council (ALEC); and
is an Honorary Commander at Nellis Air Force Base (Las Vegas, Nevada).
"With Mr. Christensen's extensive knowledge and experience in navigating government and international trade
agreements, he will spearhead our efforts in these areas. Swiss Medica is pleased to have Mr. Christensen join
our team and open up new business opportunities for our products." said Grant Johnson, Swiss Medica's
President and COO.
Mr. Christensen is a graduate of Brigham Young University, and is Managing Director of Christensen Co., an
agency specializing in business development and sales management.
About Swiss Medica, Inc.
Swiss Medica is a specialty pharmaceutical company focused on commercializing over-the-counter clinically-
tested, patented all-natural products that relieve chronic ailments. Swiss Medica builds its brands through
innovative and focused distribution and marketing strategies. Swiss Medica's mission is to be a world leader in
the commercialization of over-the-counter, safe and effective chronic ailment treatments. Please visit our
websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.
Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain
relief solution has been used and recommended for its fast-acting and long-lasting benefits by healthcare
professionals and athletes in the United States, Canada and in Europe. O24™ is widely available over-the-
counter throughout the United States and Canada in leading pharmacies and other retailers. Customers can
also visit www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica has recently launching the patented O24 Fibromyalgia™ pain reliever (US Patent #6,444,238B1)
over-the-counter in North American retailers. The National Fibromyalgia Association (NFA) recently awarded
O24 Fibromyalgia™ their first NFA Seal of Approval. Over 10 million Americans suffer from the long-term pain
associated with fibromyalgia. In a randomized double blind clinical trial conducted in 2005, 88 per cent of the
patients who used O24 Fibromyalgia™ reported mild to markedly better improvement, versus only 7 per cent
who used the placebo. Customers can also visit www.O24zone.com for ordering details and store locators for the
nearest retailer.
Swiss Medica also distributes PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS Escape® is
a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in
mood and appetite that women experience during the premenstrual period. Customers can also visit:
www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the
United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
transactions being contemplated, risks related to international sales and potential foreign currency exchange
fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's
periodic reports filed with the United States Securities and Exchange Commission and other regulatory
authorities.
For more information, please contact:
Swiss Medica, Inc.
Investor Relations Contact:
David Jones
1-866-485-4243
djones@swissmedica.com
|
|
